NEW YORK, Dec. 1, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Skye Bioscience, Inc. (NASDAQ: SKYE). Shareholders who purchased shares of SKYE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/skye-bioscience-inc-loss-submission-form/?id=179139&from=4 Accessibility Stateme ...

Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for alleged violations of the Securities Exchange Act, specifically related to misleading statements about the efficacy of its drug nimacimab [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is from November 4, 2024, to October 3, 2025, with a deadline for lead plaintiff appointments set for January 16, 2026 [2]. - The complaint alleges that Skye made false and misleading statements regarding the efficacy of nimacimab, which did not demonstrate the claimed effectiveness [2]. Group 2: Shareholder Participation - Shareholders who purchased shares during the class period are encouraged to contact the DJS Law Group for potential lead plaintiff appointments, although this is not required to participate in any recovery [2][3]. - Once registered, shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's progress at no cost [3]. Group 3: DJS Law Group's Role - DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns through advocacy [4]. - The firm represents large hedge funds and alternative asset managers, emphasizing the value of litigation claims as significant assets [4].

Core Viewpoint - Rosen Law Firm is urging investors of Skye Bioscience, Inc. to secure legal counsel before the January 16, 2026 deadline for a securities class action lawsuit related to misleading statements made by the company during the class period from November 4, 2024, to October 3, 2025 [2][6]. Group 1 - Investors who purchased Skye securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - A class action lawsuit has already been filed, and potential lead plaintiffs must act by January 16, 2026 [4]. - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting their own achievements in recovering significant amounts for investors [5]. Group 2 - The lawsuit claims that Skye Bioscience made materially false and misleading statements regarding its product nimacimab, including its effectiveness and commercial prospects, which led to investor damages when the truth was revealed [6]. - The firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company, and has consistently ranked highly in terms of settlements achieved [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Skye Bioscience, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on January 16, 2026, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Skye securities between November 4, 2024, and October 3, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must act by the lead plaintiff deadline to represent other class members [2]. - The lawsuit alleges that Skye's defendants made materially false and misleading statements regarding the effectiveness and prospects of nimacimab, leading to investor damages when the truth was revealed [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in achieving significant settlements [3]. - The firm has been recognized for its performance in securities class action settlements, including being ranked No. 1 in 2017 and consistently in the top 4 since 2013, recovering hundreds of millions for investors [3]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Skye Biosciences, Inc. due to allegations of misleading statements regarding the effectiveness of its drug nimacimab, which led to significant stock price declines following the release of disappointing clinical trial results [1][3][4]. Group 1: Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in Skye to contact them for discussing legal options, with a deadline of January 16, 2026, to seek the role of lead plaintiff in a federal securities class action [1][5]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [2]. Group 2: Allegations Against Skye - The complaint alleges that Skye and its executives violated federal securities laws by making false and misleading statements about nimacimab's effectiveness and overstating its clinical, regulatory, and commercial prospects [3]. - On October 6, 2025, Skye announced that its nimacimab did not achieve the primary endpoint of weight loss compared to placebo, resulting in a 60% drop in stock price, closing at $1.90 per share [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Skye Biosciences, Inc. due to allegations of misleading statements regarding the effectiveness of its drug nimacimab, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by January 16, 2026 [3][5]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses in Skye to discuss their legal options, particularly those who purchased securities between November 4, 2024, and October 3, 2025 [1][3]. - The firm has filed a federal securities class action against Skye, with a deadline for investors to seek lead plaintiff status by January 16, 2026 [3][7]. - The complaint alleges that Skye and its executives violated federal securities laws by making false statements about the effectiveness of nimacimab and overstating its clinical and commercial prospects [5][6]. Group 2: Stock Performance and Impact - Following the announcement of disappointing clinical trial results for nimacimab on October 6, 2025, Skye's stock price fell by $2.85 per share, or 60%, closing at $1.90 per share [6]. - The press release indicated that the primary endpoint of weight loss was not achieved in the clinical trial, and drug exposure was lower than expected, suggesting a need for higher dosing [6]. Group 3: Firm Background and Contact Information - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. - The firm encourages anyone with information regarding Skye's conduct, including whistleblowers and former employees, to contact them for further investigation [8].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Skye Bioscience, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on January 16, 2026 [1]. Group 1: Class Action Details - Investors who purchased Skye securities between November 4, 2024, and October 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The lawsuit alleges that Skye's management made materially false and misleading statements regarding the effectiveness and prospects of its product, nimacimab, leading to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in this area [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company, and has consistently ranked highly in terms of settlements recovered for investors [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Skye Bioscience, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on January 16, 2026 [1]. Group 1: Class Action Details - Investors who purchased Skye securities between November 4, 2024, and October 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - To serve as lead plaintiff, individuals must file a motion with the Court by January 16, 2026 [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company and has been ranked highly for its performance in this area [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4]. Group 3: Case Allegations - The lawsuit alleges that Skye's defendants made materially false and misleading statements regarding the effectiveness of nimacimab, overstating its clinical and commercial prospects [5]. - The claims suggest that when the true information became public, investors suffered damages due to the misleading statements made by the defendants [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Skye Bioscience, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the Skye Bioscience securities is from November 4, 2024, to October 3, 2025, inclusive [1]. - Investors who purchased Skye securities during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 16, 2026 [2]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions [3]. - Rosen Law Firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions for investors [3]. - The firm has been consistently ranked among the top firms for securities class action settlements since 2013 [3]. Group 3: Case Allegations - The lawsuit alleges that during the Class Period, defendants made materially false and misleading statements regarding Skye's business and the effectiveness of its product, nimacimab [4]. - Specifically, it is claimed that nimacimab was less effective than represented, leading to overstated clinical, regulatory, and commercial prospects [4]. - The lawsuit asserts that when the true information became public, investors suffered damages as a result [4].

Core Viewpoint - Rosen Law Firm is encouraging investors of Skye Bioscience, Inc. to secure legal counsel before the January 16, 2026 deadline for lead plaintiff applications in a securities class action lawsuit [1][3]. Group 1: Class Action Details - Investors who purchased Skye securities between November 4, 2024, and October 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 16, 2026 [3][5]. - The lawsuit alleges that defendants made materially false and misleading statements regarding Skye's business and the effectiveness of its product, nimacimab, which led to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Many attorneys at Rosen Law Firm have received recognition from Lawdragon and Super Lawyers, emphasizing the firm's expertise in this area [4].